VivoSeq
Oncology

Clinical Stage III Cutaneous Melanoma AJCC V8

9

Pipeline Programs↗

4

Active Trials↗

3

Companies Involved↗

Clinical Stage III Cutaneous Melanoma AJCC v8 is an early-stage landscape with 9 programs across 3 companies. The most active players are Roche, Bristol-Myers Squibb, Merck & Co.. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

0/100

Mech. Concentration

40/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 3Merck & Co. logo

Merck & Co.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Active, not recruiting3 · 75%
Recruiting1 · 25%

Clinical Trials

Trial Activity

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT02224781·267 enrolled
Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05136196·150 enrolled
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT02506153·1,301 enrolled
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
Active, not recruiting·FF. Stephen Hodi, MD·Phase 2·NCT04356729·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)